Soros Fund Management LLC Has $28.07 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Soros Fund Management LLC raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 230,893 shares of the biotechnology company's stock after buying an additional 24,310 shares during the quarter. Soros Fund Management LLC owned about 0.24% of Sarepta Therapeutics worth $28,074,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Manchester Capital Management LLC boosted its holdings in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after buying an additional 156 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $36,000. Steward Partners Investment Advisory LLC grew its position in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after buying an additional 194 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock valued at $54,000 after acquiring an additional 216 shares during the period. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock traded up $0.73 during midday trading on Friday, reaching $63.51. The company had a trading volume of 1,395,787 shares, compared to its average volume of 1,427,144. The stock has a fifty day simple moving average of $73.73 and a 200 day simple moving average of $104.12. Sarepta Therapeutics, Inc. has a 1-year low of $48.01 and a 1-year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $6.24 billion, a price-to-earnings ratio of 50.81 and a beta of 0.93.

Insider Activity

In related news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.70% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Needham & Company LLC decreased their price objective on Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating on the stock in a report on Thursday, April 3rd. HC Wainwright restated a "neutral" rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, April 16th. Cantor Fitzgerald reiterated an "overweight" rating and set a $163.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Scotiabank dropped their price target on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. Finally, Piper Sandler decreased their price objective on Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $158.70.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.